GlassScriptPhysician profile
Jason A Stern
NPI 1215005319
$4,584.25
in general payments reported to CMS, 2019-2025
24 companies · $45.08 in 2025
The $45.08 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $2,981 · 2021: $1,029 · 2022: $13.68 · 2023: $33.35 · 2024: $128 · 2025: $45.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,800.00 | 2020 | |
| Glaxosmithkline, LLC. | $672.31 | 2020-2021 | |
| Incyte Corporation | $199.90 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.09 | 2021 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Dova Pharmaceuticals | $94.22 | 2019 | |
| Janssen Biotech, INC. | $77.61 | 2021 | |
| Lilly USA, LLC | $69.16 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $58.75 | 2019 | |
| Stemline Therapeutics INC. | $58.75 | 2019 | |
| Amarin Pharma, INC. | $51.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $47.00 | 2019 | |
| Amgen INC. | $36.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.23 | 2019-2023 | Keytruda, Lynparza |
| Tempus Ai, INC | $28.37 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $23.62 | 2025 | Brukinsa |
| Pfizer INC. | $21.46 | 2025 | |
| Eisai INC. | $16.57 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.46 | 2021 | |
| Sumitomo Pharma America, INC. | $14.80 | 2023 | Orgovyx |
| Kite Pharma, INC. | $13.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.36 | 2021 | |
| Genentech USA, INC. | $13.19 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.